BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SIGA catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:2de3025ae1a32980a56e@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:SIGA P2 readout (est.): Study to Assess the Safety and Immunogenici
 ty of TPOXX® When Administered Orally for 28 Days With JYNNEOS
DESCRIPTION:Study to Assess the Safety and Immunogenicity of TPOXX® When A
 dministered Orally for 28 Days With JYNNEOS\nNCT04957485 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: SIGA Technologies\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker SIGA (confidence 
 0.9)\nSource: https://clinicaltrials.gov/study/NCT04957485\nScheduling/ref
 erence data from public records\; dates can move. Not investment\, legal o
 r medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04957485
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
